An established US biotech company was looking for a team of expert antibody consultants to help them understand the potential of monoclonal antibodies (mAbs) to treat bacterial infections.
Our antibody consultants conducted a high-level strategic assessment of the current antibody technologies available and their potential to treat bacterial infections. We reviewed the history of using antibodies to treat bacterial infections, including serum therapy, intravenous immunoglobulins, current and past attempts of using mAbs and current and past attempts of using polyclonal antibodies. We reviewed progress with bacterial vaccines to understand lessons learnt regarding target/antigen selection and bacterial resistance.
Our consulting team also conducted a SWOT analysis of mAb technologies that our client had encountered with respect to their applicability to bacterial infections, and suggested other technologies they should consider. Our consulting team reviewed the industry’s current pipeline of antibacterial antibodies and advised on the technical risk of each program to help guide our client’s business development strategy.
We presented our findings to a broad group of our client’s business development and R&D executives, helping shape their antibody research and licensing strategy.Back